Supplementary Table S1. Patient disposition and dose modification in patients receiving ibrutinib in the first-line and relapsed/refractory treatment settings

	First-line	
	≥65 years	**Relapsed/refractory**
	n=31	**n=101**
Median treatment duration, months (range)[a]	75 (0.3–98)	39 (0.3–98)
Treatment duration, n (%)		
≤1 year, n (%)	5 (16)	24 (24)
>1-2 years, n (%)	0	14 (14)
>2-3 years, n (%)	1 (3)	9 (9)
>3-4 years, n (%)	1 (3)	15 (15)
>4-5 years, n (%)	2 (6)	11 (11)
>5-6 years, n (%)	6 (19)	7 (7)
>6-7 years, n (%)	4 (13)	5 (5)
>7 years, n (%)	12 (39)	16 (16)
Ibrutinib exposure – 420 mg/day dose level		
Median average daily ibrutinib dose, mg/day (range)[b]	420 (317–420)	420 (175–422)

Ibrutinib exposure – 840 mg/day dose level		
Median average daily ibrutinib dose, mg/day (range)[c]	730 (576–840)	840 (563–840)
AEs leading to dose reduction, n (%)	4 (13)	19 (19)
≤1 year, n/N (%)	1/31 (3)	10/101 (10)
>1-2 years, n/N (%)	0/26 (0)	0/77 (0)
>2-3 years, n/N (%)	0/26 (0)	1/63 (2)
>3-4 years, n/N (%)	0/25 (0)	5/54 (9)
>4-5 years, n/N (%)	1/24 (4)	2/39 (5)
>5-6 years, n/N (%)	2/22 (9)	1/28 (4)
>6-7 years, n/N (%)	0/16 (0)	3/21 (14)
AEs leading to treatment discontinuation, n (%)[d]	8 (26)	29 (29)
≤1 year, n/N (%)	3/31 (10)	11/101 (11)
>1-2 years, n/N (%)	1/26 (4)	8/77 (10)
>2-3 years, n/N (%)	0/26 (0)	1/63 (2)
>3-4 years, n/N (%)	0/25 (0)	2/54 (4)
>4-5 years, n/N (%)	2/24 (8)	3/39 (8)
>5-6 years, n/N (%)	1/22 (5)	3/28 (11)

>6-7 years, n/N (%)	0/16 (0)	0/21 (0)
Primary reason for discontinuation		
Disease progression, n (%)	2 (6)	38 (38)
Adverse event, n (%)[e]	8 (26)	23 (23)
Consent withdrawal, n (%)	4 (13)	8 (8)
Investigator decision, n (%)	2 (6)	15 (15)
Lost to follow-up, n (%)	1 (3)	1 (1)

AE, adverse event.

[a]Time from first dose to last dose date if patient discontinued treatment or time from first dose to last data collection date.

[b]A total of 27 patients receiving first-line treatment and 67 patients treated for relapsed/refractory CLL/SLL received 420 mg/day ibrutinib initially in PCYC-1102.

[c]A total of 4 patients receiving first-line treatment and 34 patients treated for relapsed/refractory CLL/SLL received 840 mg/day ibrutinib initially in PCYC-1102.

[d]Includes events of Richter's transformation captured as AEs.

[e]Two patients discontinued treatment due to AEs reported outside of the AE collection period (first dose of ibrutinib until 30 days after the last dose) and thus not considered treatment-emergent.